sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension.

Conditions: Resistant Arterial Hypertension

Summary: background: in hypertension, a highly prevalent disease, up to 10-15% of hypertensive patients have uncontrolled blood pressure despite a regimen of ≥ 3 drugs, which is known as resistant hypertension (rh). cardiovascular prognosis in patients with rh is worse than in controlled hypertensives. efferent renal sympathetic nerves play an important role in volume homeostasis and blood pressure. a novel minimally invasive technique based on the use of selective radiofrequency renal sympathetic denervation has shown promising preliminary results for the treatment of these patients. on the other hand, some patients with rh could improve their blood pressure control by adding spironolactone, an antagonist of aldosterone receptors. objective: to evaluate the efficacy of radiofrequency renal sympathetic denervation in patients with rh, as compared with the addition of spironolactone to the therapeutic regimen at baseline. method: interventional, prospective, randomized, open study, of a cohort of 50 patients with rh, with office systolic blood pressure ≥ 150 mmhg and also with 24h systolic blood pressure ≥ 140 mmhg, despite treatment with ≥ 3 drugs in adequate doses, one of them a diuretic, and whitout treatment with either spironolactone or eplerenone. patients will be randomized (1:1) to renal sympathetic denervation treatment or spironolactone (50mg), performing determination of office blood pressure and 24h-abpm at pre-randomization, 1, 3 and 6 months, as well as laboratory tests, echocardiography, measurement of carotid intima-media thickness and central blood pressure measurement at pre-randomization and after 6 months.


Eligibility criteria:
inclusion criteria: 1. subjects aged ≥ 18 years and ≤ 80 years. 2. subjects with diagnosed resistant arterial hypertension (office blood pressure ≥ 140 and/or 90 mm hg despite treatment with at least 3 antihypertensive drugs given at the maximum tolerated therapeutic dosage, being one of them a diuretic), with this therapeutic regimen maintained for at least the last 3 months. 3. office systolic blood pressure ≥150 mm hg, with confirmation of resistance to treatment by 24h ambulatory blood pressure monitoring, with 24h-systolic blood pressure ≥140 mmhg being required to be included. 4. patients who have freely given informed consent in writing, after the nature of the study and the disclosure of their data have been explained to them. exclusion criteria: * 1. secondary hypertension, renovascular disease included with appropriate tests according to investigator criteria (with the exceptions of chronic renal disease and obstructive sleep-apnea syndrome). 2. inability to perform magnetic resonance angiography or renal ct angiography (contrast allergy). 3. patients unlikely compliant with treatment (assessed according to haynes-sackett test). 4. patients currently on treatment with an aldosterone receptor blocker (spironolactone, eplerenone) or who had previously received one of such class of drugs and had been withdrawn due to lack of efficacy and/or adverse effects. 5. stage 3b, 4 or 5 of chronic renal disease (estimated glomerular filtration rate by mdrd equation \< 45 ml/min/1.73m2). 6. pre-randomization serum potassium (k+) level ≥ 5.5 mmol/l. 7. significant renal vascular anomalies. 8. pregnant women. 9. significant valvular heart disease. 10. major vascular event (myocardial infarction, unstable angina or cerebrovascular disease) \< 6 months prior to study enrolment.